Zacks Investment Research upgraded shares of Emergent BioSolutions, Inc. (EBS) from NEUTRAL to OUTPERFORM on October 27, 2014, with a target price of $26.00.
We are impressed by the measures announced by Emergent BioSolutions in September this year to boost its bottom line. The company aims to drive growth by improving efficiencies and trimming its cost structure. We are also positive on the company securing a $29 million U.S. contract for developing a dry formulation of NuThrax – a next generation Anthrax vaccine. Moreover, the company's efforts to get a manufacturing facility approved which has the capacity to produce more than three times the existing amount of BioThrax is on track with the initiation of the fifth and final study needed for licensure. In view of the above positives we are upgrading the stock to Outperform.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on Emergent BioSolutions, Inc. (EBS),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment